-
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19 (opens in a new tab)
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety…
-
SAB Biotherapeutics Added to NASDAQ Biotechnology Index (opens in a new tab)
SIOUX FALLS, S.D., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel…
-
SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro (opens in a new tab)
FDA laboratory testing confirms SAB-185 neutralizes Omicron and other variants of concern with in vitro pseudovirus model SAB’s targeted, highly potent…
-
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus (opens in a new tab)
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated…
-
SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update (opens in a new tab)
Advanced SAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at interim analysis Awarded…
-
SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company (opens in a new tab)
Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under…
-
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
Registration Link Sioux Falls, S.D., October 6, 2021 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy…
-
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
Sioux Falls, S.D., October 4, 2021 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that…
-
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer
SIOUX FALLS, S.D., September 28, 2021 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that…
-
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
Advancement to Phase 3 is major milestone for SAB’s unique DiversitAbTM immunotherapy platform that produces fully-human polyclonal antibodies without…
-
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
Registration Statement on Form S-4 Has Been Declared Effective by Securities and Exchange Commission Stockholder Vote Scheduled for October 20, 2021…
-
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
$200 million total awarded to date for DiversitAb™ Rapid Response Antibody Program including Stage 4 COVID-19 Pandemic Response Expanded contract scope…